CTLA4 and glioblastoma: One such therapy includes immune checkpoint modulators, which have gained recent attention in the context of GBM, with a current phase II clinical trial investigating the effect of TMZ followed by ipilimumab, which targets PD-1 and CTLA-4, and nivolumab in recurrent GBM patients (NCT04145115) [19].